AAP
GNCA

Ardsley Advisory Partners’s Genocea Biosciences, Inc. GNCA Stock Holding History

Ardsley Advisory Partners’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,250
Closed -$119K – 252
2015
Q1 		$119K Buy
+1,250
New +$88.2K 0.02% 180

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ardsley Advisory Partners's GNCA Position: Q2 2015 in Review

Ardsley Advisory Partners sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2015, closing a stake of 1,250 shares — an estimated $119K sold.

Ardsley Advisory Partners first reported a position in GNCA in Q1 2015 and held it in 1 quarter. The position peaked at $119K in Q1 2015. 60 funds tracked by Wall St. Rank hold GNCA as of Q2 2015.

  • Ardsley Advisory Partners reported no remaining Genocea Biosciences, Inc. position as of Q2 2015 after selling out during the quarter.
  • Ardsley Advisory Partners sold 1,250 Genocea Biosciences, Inc. shares in Q2 2015, an estimated $119K.
  • Ardsley Advisory Partners first reported a position in Genocea Biosciences, Inc. in Q1 2015 and held it in 1 quarter.
  • Ardsley Advisory Partners's Genocea Biosciences, Inc. position peaked at $119K in Q1 2015.
  • 60 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2015.

Based on Ardsley Advisory Partners's 13F filing for Q2 2015, filed 14 Aug 2015.